Hidenori Wada
Overview
Explore the profile of Hidenori Wada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
406
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ishikawa T, Kawamura M, Takeshita J, Ito S, Wada H, Matsuda Y, et al.
Rinsho Ketsueki
. 2025 Feb;
65(11):1388-1392.
PMID: 39935226
We report the case of a 65-year-old man who was diagnosed with Bickerstaff brainstem encephalitis prior to central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL). He was...
2.
Gomyo A, Kako S, Kawamura M, Kawamura S, Takeshita J, Yoshino N, et al.
Int J Hematol
. 2025 Feb;
PMID: 39912986
Rapid tapering of cyclosporine (CsA) in the early phase after allogeneic transplantation may induce a potent graft-versus-leukemia/lymphoma (GVL) effect. We retrospectively reviewed the outcomes of patients with high-risk hematological malignancies...
3.
Gomyo A, Kimura S, Suzuki J, Ishikawa T, Meno T, Matsuoka A, et al.
Transplant Cell Ther
. 2023 Aug;
29(11):721.e1-721.e8.
PMID: 37643718
Clinical research regarding the impact of pretransplantation physical function on transplantation outcomes in older adults remains limited. We retrospectively reviewed the charts of 150 consecutive patients age >55 years who...
4.
Kako S, Kimura S, Wada H, Komiya Y, Nakasone H, Sakurai M, et al.
Leuk Res
. 2023 Aug;
133:107371.
PMID: 37595372
The optimal bridge strategy at the decision for allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelodysplastic syndrome (MDS) is unclear. We performed a prospective observational study in which...
5.
Matsumi S, Kimura S, Nakamura Y, Kawamura M, Takeshita J, Kawamura S, et al.
Int J Hematol
. 2023 Jul;
118(4):450-461.
PMID: 37480446
Combination of calcineurin inhibitors (CIs) with short-term methotrexate is a standard prophylactic regimen for graft-versus-host disease (GVHD). However, it is sometimes difficult to continue CIs due to adverse effects, such...
6.
Kameda K, Yanagiya R, Miyatake Y, Carreras J, Higuchi H, Murayama H, et al.
Blood
. 2023 May;
142(4):352-364.
PMID: 37146246
Aggressive natural killer cell leukemia (ANKL) is a rare lymphoid neoplasm frequently associated with Epstein-Barr virus, with a disastrously poor prognosis. Owing to the lack of samples from patients with...
7.
Nakamura Y, Kawamura S, Matsumi S, Matsumoto K, Tanaka S, Ishikawa T, et al.
Rinsho Ketsueki
. 2023 Apr;
64(4):250-254.
PMID: 37121767
A 34-year-old man with KMT2A-MLLT1 acute myeloid leukemia in first complete remission underwent allogeneic peripheral blood stem cell transplantation from his HLA-matched sister after conditioning with busulfan/cyclophosphamide. He did not...
8.
Yoshino N, Kimura S, Matsuoka A, Meno T, Ishikawa T, Nakamura Y, et al.
J Infect Chemother
. 2023 Jan;
29(4):384-390.
PMID: 36669687
Background: In autologous hematopoietic cell transplantation (HCT), myelosuppression and mucosal damage are more severe than those in conventional chemotherapy because of high-dose chemotherapy, but the duration of neutropenia is shorter...
9.
Misaki Y, Minakata D, Ibe T, Gomyo A, Yoshimura K, Kimura S, et al.
J Infect Chemother
. 2022 Nov;
29(2):212-218.
PMID: 36374666
Chronic active Epstein-Bar virus infection (CAEBV) is known to cause various symptoms. Although pulmonary artery hypertension (PAH) has been reported as a cardiovascular complication of CAEBV, the mechanisms of PAH...
10.
Yoshimura K, Kimura S, Nakasone H, Nakamura Y, Kawamura M, Kawamura S, et al.
Transplant Cell Ther
. 2022 Jun;
28(9):597.e1-597.e9.
PMID: 35750283
In general, the initial systemic treatment for chronic graft-versus-host disease (cGVHD) is 0.5 to 1 mg/kg of prednisolone (PSL). However, patients without high-risk features are sometimes treated with a calcineurin...